{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:27:40Z","timestamp":1761236860489},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2000,8,1]]},"DOI":"10.1086\/314054","type":"journal-article","created":{"date-parts":[[2002,7,26]],"date-time":"2002-07-26T18:58:36Z","timestamp":1027709916000},"page":"S16-S23","source":"Crossref","is-referenced-by-count":56,"title":["In Vitro Activity of Newer Fluoroquinolones for Respiratory Tract Infections and Emerging Patterns of Antimicrobial Resistance: Data from the SENTRY Antimicrobial Surveillance Program"],"prefix":"10.1093","volume":"31","author":[{"given":"Ronald N.","family":"Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"Pfaller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2000,8]]},"reference":[{"key":"key\n\t\t\t\t20171014010734_R1","article-title":"Initial report of a longitudinal, international antimicrobial surveillance study (SENTRY): alarming resistance rates in monitored sites (68 medical centers) in the USA, Canada, South America, and Europe [abstract E-109]. The SENTRY Study Group","volume-title":"Program and abstracts of the 37th Interscience Conference of Antimicrobial Agents and Chemotherapy (Toronto)","author":"Jones","year":"1997"},{"key":"key\n\t\t\t\t20171014010734_R2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0924-8579(99)00131-4","article-title":"Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with blood stream infections in the USA, Canada and Latin America. SENTRY Participants Group","volume":"13","author":"Diekema","year":"2000","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20171014010734_R3","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0732-8893(98)00081-9","article-title":"The prevalence of fluoroquinolone resistance among clinically significant respiratory tract isolates of Streptococcus pneumoniae in the United States and Canada: 1997 results from the SENTRY Antimicrobial Surveillance Program","volume":"32","author":"Doern","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R4","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1469-0691.1999.tb00432.x","article-title":"Antimicrobial activity evaluations of gatifloxacin, a new fluoroquinolone: contemporary pathogen results from a global antimicrobial resistance surveillance program (SENTRY, 1997). SENTRY Antimicrobial Surveillance Program Participants (The Americas)","volume":"5","author":"Jones","year":"1999","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171014010734_R5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0732-8893(98)00149-7","article-title":"Survey of blood stream infections attributable to gram-positive cocci: frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group","volume":"33","author":"Pfaller","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R6","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/S0732-8893(98)00124-2","article-title":"Antimicrobial susceptibility patterns for pathogens isolated from patients in Latin American medical centers with a diagnosis of pneumonia: analysis of results from the SENTRY Antimicrobial Surveillance Program (1997). SENTRY Latin America Study Group","volume":"32","author":"Sader","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0732-8893(96)00099-5","article-title":"The emergent needs for basic research, education, and surveillance of antimicrobial resistance. Problems facing the report from the American Society for Microbiology Task Force on Antibiotic Resistance","volume":"25","author":"Jones","year":"1996","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R8","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/S0732-8893(98)00037-6","article-title":"Bacterial resistance: a world-wide problem","volume":"31","author":"Jones","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0732-8893(98)00101-1","article-title":"Antimicrobial activity of gatifloxacin tested against 1676 strains of ciprofloxacin-resistant gram-positive cocci isolated from patient infections in North and South America","volume":"32","author":"Jones","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R10","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1128\/JCM.37.6.1999-2002.1999","article-title":"Activity of gatifloxacin against Haemophilus influenzae and Moraxella catarrhalis, including susceptibility test development, Etest comparisons, and quality control guidelines for H. influenzae","volume":"37","author":"Jones","year":"1999","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014010734_R11","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0732-8893(98)00042-X","article-title":"BAY 12-8039, a novel fluoroquinolone: activity against important respiratory tract pathogens","volume":"32","author":"Biedenbach","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0732-8893(99)00020-6","article-title":"Comparative activity of clinafloxacin and nine other compounds tested against 2000 contemporary clinical isolates from patients in United States hospitals","volume":"35","author":"Deshpande","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R13","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1164\/ajrccm.153.5.8630626","article-title":"Hospital-acquired pneumonia in adults: diagnosis, assessment of severity, initial antimicrobial therapy, and preventive strategies: a consensus statement","volume":"153","author":"American Thoracic Society","year":"1996","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171014010734_R14","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1086\/513953","article-title":"Community-acquired pneumonia in adults: guidelines for management. Infectious Disease Society of America","volume":"26","author":"Bartlett","year":"1998","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R15","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0732-8893(98)00161-8","article-title":"The diagnosis and treatment challenges in nosocomial pneumonia","volume":"33","author":"Baughman","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R16","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0732-8893(98)00072-8","article-title":"Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997\u20131998 respiratory infection season","volume":"32","author":"Jones","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network","volume":"341","author":"Chen","year":"1999","journal-title":"N Eng J Med"},{"key":"key\n\t\t\t\t20171014010734_R18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1001\/jama.1996.03530260048030","article-title":"Prognosis and outcomes of patients with community-acquired pneumonia: a meta-analysis","volume":"275","author":"Fine","year":"1996","journal-title":"JAMA"},{"key":"key\n\t\t\t\t20171014010734_R19","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1378\/chest.102.5.1562","article-title":"Pneumonia due to Haemophilus influenzae among mechanically ventilated patients: incidence, outcome, and risk factors","volume":"102","author":"Rello","year":"1992","journal-title":"Chest"},{"key":"key\n\t\t\t\t20171014010734_R20","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1164\/ajrccm.158.6.9610069","article-title":"Epidemiology of ventilator-acquired pneumonia based on protected bronchoscopic sampling","volume":"158","author":"George","year":"1998","journal-title":"Am J Respir Crit Care Med"},{"key":"key\n\t\t\t\t20171014010734_R21","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0732-8893(97)00247-2","article-title":"In vitro evaluation of sparfloxacin activity and spectrum against 24,940 pathogens isolated in the United States and Canada, the final analysis. SPAR Study Group","volume":"31","author":"Jones","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R22","article-title":"Antimicrobial activity of trovafloxacin tested against Streptococcus pneumoniae isolated in 1998\u201399: the second year report of comparative spectrum using isolates from >300 medical centers [abstract C-421]. Trovafloxacin Study Group","volume-title":"Abstracts in Clinical Microbiology","author":"Jones","year":"1999"},{"key":"key\n\t\t\t\t20171014010734_R23","doi-asserted-by":"crossref","first-page":"239","DOI":"10.3201\/eid0402.980211","article-title":"Multiple-drug resistant enterococci: the nature of the problem and an agenda for the future","volume":"4","author":"Huycke","year":"1998","journal-title":"Emerg Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R24","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1128\/AAC.42.7.1762","article-title":"Bacterial pathogens isolated from patients with blood stream infection: frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program. SENTRY Participants Group","volume":"42","author":"Pfaller","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010734_R25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0732-8893(97)00115-6","article-title":"Nosocomial enterococcal blood stream infections in the SCOPE Program: antimicrobial resistance, species occurrence, molecular testing results, and laboratory testing accuracy. SCOPE Hospital Study Group","volume":"29","author":"Jones","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R26","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0732-8893(98)00108-4","article-title":"Epidemiologic trends in nosocomial and community-acquired infections due to antibiotic-resistant gram-positive bacteria: the role of streptogramins and other newer compounds","volume":"33","author":"Jones","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R27","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0732-8893(98)00105-9","article-title":"Antimicrobial activity of SCH 27899 (Ziracin), a novel everninomicin derivative, tested against Streptococcus spp.: disk diffusion\/Etest method evaluations and quality control guidelines. Quality Control Study Group","volume":"33","author":"Marshall","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R28","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0732-8893(96)00219-2","article-title":"A 1994\u201395 survey of Haemophilus influenzae susceptibility to ten orally administered agents: a 187 clinical laboratory center sample in the United States","volume":"27","author":"Jones","year":"1997","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R29","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1128\/AAC.34.11.2075","article-title":"Antimicrobial resistance among respiratory isolates of Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae in the United States","volume":"34","author":"Jorgensen","year":"1990","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010734_R30","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0732-8893(95)00028-9","article-title":"A survey of \u03b2-lactamase-producing Haemophilus influenzae: an evaluation of 5750 isolates","volume":"21","author":"Rittenhouse","year":"1995","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R31","article-title":"Fluoroquinolone resistance in H. influenzae and M. catarrhalis: frequency of occurrence and strain characteristics in the SENTRY Antimicrobial Surveillance Program (1997\u201399; North America) [abstract 54]","volume-title":"Abstracts of the International Congress of Antimicrobial Agents and Chemotherapy","author":"Biedenbach","year":"1999"},{"key":"key\n\t\t\t\t20171014010734_R32","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0732-8893(98)00083-2","article-title":"Fluoroquinolone-resistant Moraxella catarrhalis in a patient with pneumonia: report from the SENTRY Antimicrobial Surveillance Program (1998)","volume":"32","author":"DiPersio","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"key\n\t\t\t\t20171014010734_R33","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1128\/AAC.40.4.891","article-title":"Emergence of high rates of antimicrobial resistance among viridans group streptococci in the United States","volume":"40","author":"Doern","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20171014010734_R34","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1086\/598621","article-title":"Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia","volume":"29","author":"Jones","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"key\n\t\t\t\t20171014010734_R35","doi-asserted-by":"crossref","first-page":"S48","DOI":"10.1111\/j.1469-0691.1997.tb00646.x","article-title":"The role of fourth-generation cephalosporins in the treatment of infections caused by penicillin-resistant streptococci","volume":"3","author":"Klugman","year":"1997","journal-title":"Clin Microbiol Infect"},{"key":"key\n\t\t\t\t20171014010734_R36","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0002-9343(98)00149-1","article-title":"The emergence of Staphylococcus aureus with reduced susceptibility to vancomycin in Japan","volume":"104","author":"Hiramatsu","year":"1998","journal-title":"Am J Med"},{"key":"key\n\t\t\t\t20171014010734_R37","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1128\/JCM.36.4.1020-1027.1998","article-title":"Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides","volume":"36","author":"Tenover","year":"1998","journal-title":"J Clin Microbiol"},{"key":"key\n\t\t\t\t20171014010734_R38","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0732-8893(97)00212-5","article-title":"Staphylococcus aureus and coagulase-negative staphylococci from blood stream infections: frequency of occurrence, antimicrobial susceptibility, and molecular (mec A) characterization of oxacillin resistance in the SCOPE Program","volume":"30","author":"Marshall","year":"1998","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/31\/Supplement_2\/S16\/20902812\/31-Supplement_2-S16.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T05:42:58Z","timestamp":1583300578000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/cid\/article\/31\/Supplement_2\/S16\/483514\/In-Vitro-Activity-of-Newer-Fluoroquinolones-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,8,1]]},"references-count":38,"journal-issue":{"issue":"Supplement_2","published-online":{"date-parts":[[2000,8]]},"published-print":{"date-parts":[[2000,8,1]]}},"URL":"https:\/\/doi.org\/10.1086\/314054","relation":{},"ISSN":["1537-6591","1058-4838"],"issn-type":[{"value":"1537-6591","type":"electronic"},{"value":"1058-4838","type":"print"}],"subject":[],"published-other":{"date-parts":[[2000,8]]},"published":{"date-parts":[[2000,8,1]]}}}